摘要
目的:了解新冠肺炎疫情期间,发热门诊新型冠状病毒肺炎疑似患者的药物治疗情况。方法:通过电子处方系统,导出发热门诊新型冠状病毒肺炎疑似患者的所有处方,用SPSS进行统计分析。结果:2020年1月5日至2020年2月23日,发热门诊疑似患者3 549例,其中男性为1 661例(46.8%),平均年龄为48±15.1岁,高发年龄段为40~60岁,1 482例(41.8%)。2020年1月22日至2月8日,最高日处方数达到764张。所有患者均给予了抗病毒和抗感染治疗。13 645张处方,含有抗病毒药物的处方有7 174张(52.6%),其中单用抗病毒西药为阿比朵尔1 491(20.8%),更昔洛韦1 962(27.3%),中成药为连花清瘟或金叶败毒1 578(22.0%),中西联用处方有阿比朵尔+(莲花清瘟或金叶败毒)1 397(19.5%)和更昔洛韦注射液+(莲花清瘟或金叶败毒)299(4.2%);含有抗感染治疗的处方有6 781(49.7%)张,主要药物为莫西沙星,6 118(90.2%)。其中有349(10.1%)位患者使用了糖皮质激素治疗,且男性偏多。449(12.6%)名患者进行了免疫疗法。结论:发热门诊新冠肺炎疑似患者的药物治疗基本按流感病毒,中东呼吸综合征(MERS)和严重急性呼吸综合征(SARS)的治疗经验进行早期的抗病毒,抗感染,营养支持及对症治疗等方式进行,对于重症患者使用了糖皮质激素治疗和免疫疗法。
OBJECTIVE To investigate the drug treatment of suspected patients with COVID-19 in fever clinic during the epidemic period.METHODS All prescriptions of suspected COVID-19 in fever clinic were collected by electronic prescription system and analyzed by SPSS.RESULTS From January 5,2020 to February 3,2020,there were 3 549 suspected patients with COVID-19 in fever clinic,with an average age of 48±15.1,1 661(46.8%)in males,and the age group with the highest incidence was 40-60 years with 1 482 cases(41.8%)..The highest number of prescriptions for the outpatients in fever clinic were 764 from January 22,to February 8,2020.All patients were received antiviral therapy and antibacterial therapy.The number of all the prescriptions were 13 645.There were 7 174 prescriptions containing antiviral drugs(52.6%),of which abidor 1 491(20.8%),ganciclovir 1 962(27.3%),Lianhuaqingwen or Jinyebaidu 1 578(22.0%),abidor +(Lianhuaqingwen or Jinyebaidu)1 397(19.5%)and Ganciclovir injection +(Lianhuaqingwen or Jinyebaidu)299(4.2%);there were 6 781(49.7%)prescriptions containing anti antibacterial treatment,and the main drug was moxifloxacin,6 118(90.2%).Among them,349(10.1%)patients were treated with glucocorticoids,especially in male patients.449(12.6%)patients received immunotherapy.CONCLUSIONS The drug treatment of suspected patients with COVID-19 in fever clinic is basically based on the treatment experience of influenza virus,Middle East respiratory syndrome(MERS)and severe acute respiratory syndrome(SARS)for early antiviral,anti-infection,nutritional support and symptomatic treatment.Glucocorticoid therapy and immunotherapy are used for critically ill patients.
作者
卢圆圆
李伟杰
刘东
李娟
LU Yuan-yuan;LI Wei-jie;LIU Dong;LI Juan(Department of Pharmacy,Tongji Hospital Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430000,China)
出处
《中国医院药学杂志》
CAS
北大核心
2020年第12期1296-1299,1338,共5页
Chinese Journal of Hospital Pharmacy
